IgG4 subclass antibodies impair antitumor immunity in melanoma. - Wikidata - awgldk - TriplyDB

IgG4 subclass antibodies impair antitumor immunity in melanoma.

IgG4 subclass antibodies impair antitumor immunity in melanoma.

http://www.wikidata.org/entity/Q36733452

about

IgG4 Characteristics and Functions in Cancer Immunity Emerging blood-based biomarkers for detection of gastric cancer Human IgG4: a structural perspective Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer Pathways and therapeutic targets in melanoma Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach IgE-based immunotherapy of cancer: challenges and chances.B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection.A tool kit for rapid cloning and expression of recombinant antibodies.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma Evaluating biomarkers in melanoma.Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.A subset of ocular adnexal marginal zone lymphomas may arise in association with IgG4-related disease Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells.Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.IgE immunotherapy: a novel concept with promise for the treatment of cancer.Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?IgG4-associated cholangitis: a comprehensive review.Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 antibodies on IgE-activated granulocytes.AllergoOncology - the impact of allergy in oncology: EAACI position paper.Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models.The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Robo4 vaccines induce antibodies that retard tumor growth.Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

P2860

Q26770244-DF9CF52E-91D0-4F6F-91F6-0A847FB45EBD Q26778026-0B553177-4069-4965-B658-20E8D9657E91 Q26779758-3E8699F2-D813-4C5C-BADA-497BAD433F59 Q26865509-C6D0436B-73CC-4ECA-8534-A2321F79742C Q26865736-8A18E0A4-8F80-414B-892E-7AB2F0ADCACA Q28076193-A8B7371C-82AF-4F1A-BB9E-4F468D5D2D26 Q28655505-5578594C-C2D9-4AE5-95EC-CD96FA5FA4D4 Q33619979-8634FE04-F258-4AA6-87D7-F95CFE805B4F Q33632113-9AB4F4C6-0277-4AAB-AB7E-6B14B516E021 Q33820823-0243CA64-FA02-428C-91C3-2871D375428B Q33970343-7A2C4226-110C-4ECC-BEB3-1255CB8A61DF Q34000700-64926BA3-D1C0-4530-90A7-F90E112BC95A Q34646279-8B732A9D-0D77-4986-B9C5-D39869B3CD20 Q35005677-2126A71E-FFB1-400A-A6BB-5BF336F802A6 Q35273555-C27F2C52-410A-4AA1-95AF-3B3D47690A7B Q35999504-C0FD556C-98D6-4077-A63D-CB0034549E8E Q36003561-B0E66672-F8A6-45A6-B6DC-B9F25BECCBA3 Q36089397-4408041E-F993-418D-866D-F73AC9E11A70 Q36110293-CDFC2165-555A-4B7C-BC02-9E5EEFDE72C5 Q36584020-03A6A070-C769-4C4C-B2F3-E54F7A39F2E3 Q36597345-EB0F51CE-4AEC-435A-948A-88947E81071B Q37093267-737CB29A-1565-475F-86EC-19EB59F632A2 Q37195202-D5D8A403-AC2C-4815-BF2D-E84288B918D8 Q37559274-BDA405CE-C72D-45F6-8EE9-B69D905A2A3C Q37582041-EB36A5FE-0322-48B4-9BB1-DA6339520651 Q37593712-249CC00D-6D84-4AA6-8AF3-1C50EA4BB3CE Q38201655-98B92B74-D8B7-4A99-A075-6B5CA5093239 Q38222686-D22AF816-AFCC-4711-907A-9A283AD35CF8 Q38635910-FBD7ACB4-CE5F-435B-8AFB-19BA79267A40 Q38662580-C9FAC359-E038-479C-BB8B-A149B16832D5 Q38776716-EC42D24C-B505-4525-8FB1-0B1DC2EA2E0A Q38827936-9201B099-713A-4F53-A75B-E03811128363 Q38843707-235BE1A6-1686-47C3-85B3-25FA2B4A9056 Q39172481-4EAB9BCA-195E-4C4C-A6EB-C5785CC5A360 Q39646994-49914FB1-7191-472E-8DC2-0C5B4AA0F0CF Q40915404-6623CA65-EFC8-4121-8D22-A0E2C1FA0AED Q41573243-5EA86AE6-1412-4F50-A41A-EB089C4ABC2A Q41673094-BF93F524-C337-475B-BDEC-835BAF6B83DF Q41687753-A487F4CB-4ADB-4985-96CE-4D03B4E44B63 Q42230293-8188CCDC-92C2-4D7C-BCBC-3EE6A5A980FF

P2860

IgG4 subclass antibodies impair antitumor immunity in melanoma.

http://www.wikidata.org/entity/Q36733452

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@ast

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@en

type

label

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@ast

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@en

prefLabel

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@ast

IgG4 subclass antibodies impair antitumor immunity in melanoma.

@en

P1433

Q36733452-A28DB856-DC95-4AA6-9C8B-35DCDD3FE59B

P1476

Q36733452-3B7D643B-0DA1-45CF-8DFF-534F34E963C8

P2093

Q36733452-01063D53-958C-48F1-9851-B59350C19E17

Q36733452-1AAFF606-8EF6-4166-96BD-520B50790906

Q36733452-2D2E722A-9D24-4CA7-99A4-9E03D54E0528

Q36733452-304587A0-8CC3-4CC7-A773-6E4CE136D163

Q36733452-392EBF82-AA61-441A-945F-EE2782F13F33

Q36733452-3EC2E286-26BD-4300-A65C-E5F7AE3B26B7

Q36733452-4A367FAB-44A0-41AF-A388-B2362A0DCC6E

Q36733452-5199EBDD-3644-4A71-8764-EEBDB98C6F36

Q36733452-62744073-EBE5-425D-841A-3B9F3B86D7A6

Q36733452-719A7704-8976-4AD9-8ED7-852B8DD04A8C

P2860

Q36733452-0265E05B-7AF1-4030-8EB6-247F73642271

Q36733452-03BB74D4-A393-40C9-813E-B4EA1E2EBC2D

Q36733452-053CB0BE-E002-4A21-B9FE-84CAACE2C166

Q36733452-07F2BC69-06F8-4682-A5FA-8FF69D8DE2B7

Q36733452-100387A9-F4C5-44A7-A56E-5B0A393BC825

Q36733452-12F16354-68BD-4E4D-8417-F4B400A1E11E

Q36733452-131DE3A9-2105-4450-B564-FD2EA84D8709

Q36733452-14FEDEC9-F33E-4A9D-B89B-73C9ACC45B08

Q36733452-17743625-CFAF-4C78-9BCD-26CB915432C0

Q36733452-1984F07E-D4E2-4EC1-9106-F4F8CBBE4B7F

P304

Q36733452-4C62D0C7-F606-41D0-9B9B-2221CBA1DBEB

P31

Q36733452-0332A47B-9D9E-4BB4-B2A1-A33A90FE9B3D

P356

Q36733452-BA6A0DF1-693F-4B97-8E60-E0E3281731EF

P407

Q36733452-3FEF10A4-43FA-440A-AD1C-29A13ECD6B4E

P433

Q36733452-7BBD3208-E449-4957-873B-88B17A197B51

P478

Q36733452-506918EF-AD89-48AC-8C90-FF0E486A7388

P50

Q36733452-46E580FC-C558-49D6-9508-3F076FD6B32A

Q36733452-5AFE01B3-F34B-4DC7-A2AD-F9D597954B95

Q36733452-63E433BF-9625-4405-836B-DD44EDF9B35B

Q36733452-BFFD348A-0812-413B-9276-A24D62CCCC22

P577

Q36733452-0F4B3E1E-8149-4ECA-8A7D-701460740B03

P5875

Q36733452-1956250C-CFF9-4D32-92D9-9DEF6D7B7AE7

P698

Q36733452-072E3BEF-78C1-4535-BED9-5A2A55B9DA3A

P921

Q36733452-2960AE3D-E04E-420E-95DF-E78324F25C30

P932

Q36733452-8EA1AD23-452A-4C9F-9BA9-9217EA4C7834

P356

P1433

Journal of Clinical Investigation

P1476

IgG4 subclass antibodies impair antitumor immunity in melanoma

@en

P2093

Alexander Koers

http://www.w3.org/2001/XMLSchema#string

Amy E Gilbert

http://www.w3.org/2001/XMLSchema#string

Carl Hobbs

http://www.w3.org/2001/XMLSchema#string

Ciaran Healy

http://www.w3.org/2001/XMLSchema#string

Debra H Josephs

http://www.w3.org/2001/XMLSchema#string

Frank O Nestle

http://www.w3.org/2001/XMLSchema#string

Isabel Correa

http://www.w3.org/2001/XMLSchema#string

James F Spicer

http://www.w3.org/2001/XMLSchema#string

Jenny L C Geh

http://www.w3.org/2001/XMLSchema#string

Katharine M Acland

http://www.w3.org/2001/XMLSchema#string

P2860

Eradication of melanomas by targeted elimination of a minor subset of tumor cells

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies

IgG4-related disease

Final version of 2009 AJCC melanoma staging and classification

Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study.

Mechanisms of tolerance to inhalant allergens: the relevance of a modified Th2 response to allergens from domestic animals.

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

Hyper-IgG4 disease: report and characterisation of a new disease.

Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity

P304

1457-1474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI65579

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Philip J Blower

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235775793

http://www.w3.org/2001/XMLSchema#string

P698

23454746

http://www.w3.org/2001/XMLSchema#string

P921

P932

3613918

http://www.w3.org/2001/XMLSchema#string